Bora Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bora Lee has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Dhiraj Kumar Sah
Department of Biochemistry, Department of Biomedical Sciences, Chonnam National University Medical School, Gwangju 501190, Republic of Korea
3 shared publications - Young Do Jung
Department of Biochemistry, Chonnam National University Medical School, Hwasun 58128, Republic of Korea
3 shared publications - Archana Arjunan
Department of Biochemistry, Chonnam National University Medical School, Hwasun 58128, Republic of Korea
2 shared publications Archana Arjunan
Department of Biochemistry, Chonnam National University Medical School, Hwasun, Republic of Korea
1 shared publicationJanghyun Kim
Chonnam National University
1 shared publication- Janghyun Kim
Department of Oral Pathology, School of Dentistry, Chonnam National University, Gwangju 61186, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 30 January 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1498213
Triptolide suppresses IL-1β-induced expression of interleukin-8 by inhibiting ROS-Mediated ERK, AP-1, and NF-κB molecules in human gastric cancer AGS cells
Triptolide, the major component of Chinese herbal medicine Tripterygium wilfordii Hook F, possesses potent anticancer and anti-inflammatory effects. IL-8, a proinflammatory cytokine, is associated with cancer cell proliferation and angiogenesis. Here, we found that Triptolide has an inhibitory effect on IL-1β-induced IL-8 expression in human gastric cancer cells, via the suppression of reactive oxygen species (ROS) production, AP-1, and NF-κB activation, which in turn affects human endothelial cell angiogenetic activity in tumor microenvironments. Human gastric AGS cells were treated with IL-1β (10 ng/mL) and Triptolide (0–20 nM), and the ROS generation, ERK, AP-1, and NF-κB signaling were all investigated. These results demonstrate that Triptolide inhibits the IL-1β-induced IL-8 expression in gastric cancer cells by inhibiting ROS production and angiogenesis, via the dose-dependent attenuation of ERK, AP-1, and NF-κB activation. In this study, we showed that Triptolid inhibits ROS/ERK-mediated AP-1 and ROS-mediated NF-κB axes potentially leading to an improved treatment outcome for gastric cancer and its associated tumor microenvironment.
- 30 January 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1498213
Open AccessTriptolide suppresses IL-1β-induced expression of interleukin-8 by inhibiting ROS-Mediated ERK, AP-1, and NF-κB molecules in human gastric cancer AGS cells
Triptolide, the major component of Chinese herbal medicine Tripterygium wilfordii Hook F, possesses potent anticancer and anti-inflammatory effects. IL-8, a proinflammatory cytokine, is associated with cancer cell proliferation and angiogenesis. Here, we found that Triptolide has an inhibitory effect on IL-1β-induced IL-8 expression in human gastric cancer cells, via the suppression of reactive oxygen species (ROS) production, AP-1, and NF-κB activation, which in turn affects human endothelial cell angiogenetic activity in tumor microenvironments. Human gastric AGS cells were treated with IL-1β (10 ng/mL) and Triptolide (0–20 nM), and the ROS generation, ERK, AP-1, and NF-κB signaling were all investigated. These results demonstrate that Triptolide inhibits the IL-1β-induced IL-8 expression in gastric cancer cells by inhibiting ROS production and angiogenesis, via the dose-dependent attenuation of ERK, AP-1, and NF-κB activation. In this study, we showed that Triptolid inhibits ROS/ERK-mediated AP-1 and ROS-mediated NF-κB axes potentially leading to an improved treatment outcome for gastric cancer and its associated tumor microenvironment.
- Open Access
- 28 March 2024
- Published by MDPI AG in Antioxidants
- Vol. 13 (4) , 406
Sulforaphane Inhibits IL-1β-Induced IL-6 by Suppressing ROS Production, AP-1, and STAT3 in Colorectal Cancer HT-29 Cells
Colorectal cancer (CRC) stands as a major cause of cancer-related mortality globally, accounting for approximately 881,000 deaths each year. Traditional approaches such as chemotherapy and surgery have been the primary treatment modalities, yet the outcomes for patients with metastatic CRC are often unsatisfactory. Recent research has focused on targeting the pathways involved in oxidative stress, inflammation, and metastasis to enhance the survival of CRC patients. Within this context, sulforaphane (SFN), a notable phytochemical found predominantly in cruciferous vegetables, has been recognized as a potential anticancer agent. However, the specific mechanisms through which SFN may exert its chemopreventive effects in CRC remain unclear. This study explores the impact of SFN on IL-1β-induced IL-6 activation and MAPK and AP-1 signaling in HT-29 cells. Our findings reveal that SFN treatment not only diminishes IL-1β-stimulated IL-6 expression but also reduces oxidative stress by curtailing reactive oxygen species (ROS) production. Furthermore, it hinders the proliferation and invasiveness of HT-29 cells through the modulation of MAPK/AP-1 and STAT3 signaling pathways. These results indicate that SFN mitigates IL-1β-induced IL-6 expression in CRC cells by attenuating ROS production and disrupting MAPK/AP-1 signaling. This suggests that SFN holds significant potential as a chemotherapeutic agent for both treating and preventing CRC.
- 28 March 2024
- Published by MDPI AG in Antioxidants
- Vol. 13 (4) , 406
Open AccessSulforaphane Inhibits IL-1β-Induced IL-6 by Suppressing ROS Production, AP-1, and STAT3 in Colorectal Cancer HT-29 Cells
Colorectal cancer (CRC) stands as a major cause of cancer-related mortality globally, accounting for approximately 881,000 deaths each year. Traditional approaches such as chemotherapy and surgery have been the primary treatment modalities, yet the outcomes for patients with metastatic CRC are often unsatisfactory. Recent research has focused on targeting the pathways involved in oxidative stress, inflammation, and metastasis to enhance the survival of CRC patients. Within this context, sulforaphane (SFN), a notable phytochemical found predominantly in cruciferous vegetables, has been recognized as a potential anticancer agent. However, the specific mechanisms through which SFN may exert its chemopreventive effects in CRC remain unclear. This study explores the impact of SFN on IL-1β-induced IL-6 activation and MAPK and AP-1 signaling in HT-29 cells. Our findings reveal that SFN treatment not only diminishes IL-1β-stimulated IL-6 expression but also reduces oxidative stress by curtailing reactive oxygen species (ROS) production. Furthermore, it hinders the proliferation and invasiveness of HT-29 cells through the modulation of MAPK/AP-1 and STAT3 signaling pathways. These results indicate that SFN mitigates IL-1β-induced IL-6 expression in CRC cells by attenuating ROS production and disrupting MAPK/AP-1 signaling. This suggests that SFN holds significant potential as a chemotherapeutic agent for both treating and preventing CRC.
- Open Access
- 2 September 2023
- Published by MDPI AG in Antioxidants
- Vol. 12 (9) , 1712
Reactive Oxygen Species and H. pylori Infection: A Comprehensive Review of Their Roles in Gastric Cancer Development
Gastric cancer (GC) is the fifth most common cancer worldwide and makes up a significant component of the global cancer burden. Helicobacter pylori (H. pylori) is the most influential risk factor for GC, with the International Agency for Research on Cancer classifying it as a Class I carcinogen for GC. H. pylori has been shown to persist in stomach acid for decades, causing damage to the stomach’s mucosal lining, altering gastric hormone release patterns, and potentially altering gastric function. Epidemiological studies have shown that eliminating H. pylori reduces metachronous cancer. Evidence shows that various molecular alterations are present in gastric cancer and precancerous lesions associated with an H. pylori infection. However, although H. pylori can cause oxidative stress-induced gastric cancer, with antioxidants potentially being a treatment for GC, the exact mechanism underlying GC etiology is not fully understood. This review provides an overview of recent research exploring the pathophysiology of H. pylori-induced oxidative stress that can cause cancer and the antioxidant supplements that can reduce or even eliminate GC occurrence.
- 2 September 2023
- Published by MDPI AG in Antioxidants
- Vol. 12 (9) , 1712
Open AccessReactive Oxygen Species and H. pylori Infection: A Comprehensive Review of Their Roles in Gastric Cancer Development
Gastric cancer (GC) is the fifth most common cancer worldwide and makes up a significant component of the global cancer burden. Helicobacter pylori (H. pylori) is the most influential risk factor for GC, with the International Agency for Research on Cancer classifying it as a Class I carcinogen for GC. H. pylori has been shown to persist in stomach acid for decades, causing damage to the stomach’s mucosal lining, altering gastric hormone release patterns, and potentially altering gastric function. Epidemiological studies have shown that eliminating H. pylori reduces metachronous cancer. Evidence shows that various molecular alterations are present in gastric cancer and precancerous lesions associated with an H. pylori infection. However, although H. pylori can cause oxidative stress-induced gastric cancer, with antioxidants potentially being a treatment for GC, the exact mechanism underlying GC etiology is not fully understood. This review provides an overview of recent research exploring the pathophysiology of H. pylori-induced oxidative stress that can cause cancer and the antioxidant supplements that can reduce or even eliminate GC occurrence.
- Open Access
Identification of Long Non-Coding RNA Profiles and Potential Therapeutic Agents for Fibrolamellar Carcinoma Based on RNA-Sequencing Data
Background: Fibrolamellar carcinoma (FLC) is a rare type of liver cancer that primarily affects adolescents and young adults without prior liver disease or viral infections. Patients with FLC generally have non-specific symptoms, are often diagnosed at a later stage, and experience a higher frequency of metastases compared to patients with other liver cancers. A fusion transcript of DNAJB1 and PRKACA, which can lead to increased activity of PKA and cellular proliferation, has been identified in all FLC patients, but the exact mechanism through which FLC develops remains unclear. In this study, we investigated common lncRNA profiles in various FLC samples using bioinformatics analyses. Methods: We analyzed differentially expressed (DE) lncRNAs from three RNA sequencing datasets. Using lncRNAs and DE mRNAs, we predicted potential lncRNA target genes and performed Gene Ontology (GO) and KEGG analyses with the DE lncRNA target genes. Moreover, we screened for small-molecule compounds that could act as therapeutic targets for FLC. Results: We identified 308 DE lncRNAs from the RNA sequencing datasets. In addition, we performed a trans-target prediction analysis and identified 454 co-expressed pairs in FLC. The GO analysis showed that the lncRNA-related up-regulated mRNAs were enriched in the regulation of protein kinase C signaling and cAMP catabolic processes, while lncRNA-related down-regulated mRNAs were enriched in steroid, retinol, cholesterol, and xenobiotic metabolic processes. The analysis of small-molecule compounds for FLC treatment identified vitexin, chlorthalidone, triamterene, and amiloride, among other compounds. Conclusions: We identified potential therapeutic targets for FLC, including lncRNA target genes as well as small-molecule compounds that could potentially be used as treatments. Our findings could contribute to furthering our understanding of FLC and providing potential avenues for diagnosis and treatment.
Open AccessIdentification of Long Non-Coding RNA Profiles and Potential Therapeutic Agents for Fibrolamellar Carcinoma Based on RNA-Sequencing Data
Background: Fibrolamellar carcinoma (FLC) is a rare type of liver cancer that primarily affects adolescents and young adults without prior liver disease or viral infections. Patients with FLC generally have non-specific symptoms, are often diagnosed at a later stage, and experience a higher frequency of metastases compared to patients with other liver cancers. A fusion transcript of DNAJB1 and PRKACA, which can lead to increased activity of PKA and cellular proliferation, has been identified in all FLC patients, but the exact mechanism through which FLC develops remains unclear. In this study, we investigated common lncRNA profiles in various FLC samples using bioinformatics analyses. Methods: We analyzed differentially expressed (DE) lncRNAs from three RNA sequencing datasets. Using lncRNAs and DE mRNAs, we predicted potential lncRNA target genes and performed Gene Ontology (GO) and KEGG analyses with the DE lncRNA target genes. Moreover, we screened for small-molecule compounds that could act as therapeutic targets for FLC. Results: We identified 308 DE lncRNAs from the RNA sequencing datasets. In addition, we performed a trans-target prediction analysis and identified 454 co-expressed pairs in FLC. The GO analysis showed that the lncRNA-related up-regulated mRNAs were enriched in the regulation of protein kinase C signaling and cAMP catabolic processes, while lncRNA-related down-regulated mRNAs were enriched in steroid, retinol, cholesterol, and xenobiotic metabolic processes. The analysis of small-molecule compounds for FLC treatment identified vitexin, chlorthalidone, triamterene, and amiloride, among other compounds. Conclusions: We identified potential therapeutic targets for FLC, including lncRNA target genes as well as small-molecule compounds that could potentially be used as treatments. Our findings could contribute to furthering our understanding of FLC and providing potential avenues for diagnosis and treatment.
- Open Access
- 16 May 2023
- Published by Springer Nature in Research Square
Identification of mRNA and lncRNA profiles and potential targeted agents for fibrolamellar carcinoma based on RNA-sequencing data
Background: Fibrolamellar carcinoma (FLC) is a rare type of liver cancer that primarily affects adolescents and young adults without prior liver disease or virus infections. Patients with FLC often have non-specific symptoms and are often diagnosed at a later stage with a higher frequency of metastases compared to other liver cancers. A fusion transcript of DNAJB1 and PRKACA has been identified in all FLC patients, which can lead to increased activity of PKA and cellular proliferation, although the exact mechanism through which FLC develops remains unclear. In this study, we investigated common mRNA and lncRNA profiles in various FLC samples using bioinformatics analysis. Methods: We analyzed differentially expressed mRNAs and lncRNAs from three different public datasets. We performed Gene Ontology (GO), KEGG, and Protein-Protein Interaction (PPI) Network analyses with the differentially expressed (DE) mRNAs of FLC. Using DE mRNAs and lncRNAs, we predicted potential lncRNA target genes and screened for small molecule compounds for the FLC. Results: We identified 912 differentially expressed mRNAs and 308 differentially expressed lncRNAs from RNA sequencing analysis. GO analysis showed that the upregulated mRNAs in FLC were enriched in collagen fibril and extracellular matrix organization, while the downregulated mRNAs were enriched in xenobiotic metabolic and exogenous drug catabolic process. Furthermore, the upregulated mRNAs were enriched in PI3k-Akt signaling pathway based on KEGG pathway analysis, and in epithelial mesenchymal transition from GSEA analysis. we performed trans-target prediction analysis and identified 454 co-expressed pairs in FLC. Lastly, we screened and obtained potential therapeutic small molecule compounds using hub genes of FLC we identified. Conclusions: Our study revealed common mRNA and lncRNA expression profiles in FLC, and identified hub genes of DE mRNAs and lncRNA target genes, as well as small molecular compounds that could potentially be used as treatments. These results could contribute to further understanding of FLC and provides potential avenues for diagnosis and treatment.
- 16 May 2023
- Published by Springer Nature in Research Square
Open AccessIdentification of mRNA and lncRNA profiles and potential targeted agents for fibrolamellar carcinoma based on RNA-sequencing data
Background: Fibrolamellar carcinoma (FLC) is a rare type of liver cancer that primarily affects adolescents and young adults without prior liver disease or virus infections. Patients with FLC often have non-specific symptoms and are often diagnosed at a later stage with a higher frequency of metastases compared to other liver cancers. A fusion transcript of DNAJB1 and PRKACA has been identified in all FLC patients, which can lead to increased activity of PKA and cellular proliferation, although the exact mechanism through which FLC develops remains unclear. In this study, we investigated common mRNA and lncRNA profiles in various FLC samples using bioinformatics analysis. Methods: We analyzed differentially expressed mRNAs and lncRNAs from three different public datasets. We performed Gene Ontology (GO), KEGG, and Protein-Protein Interaction (PPI) Network analyses with the differentially expressed (DE) mRNAs of FLC. Using DE mRNAs and lncRNAs, we predicted potential lncRNA target genes and screened for small molecule compounds for the FLC. Results: We identified 912 differentially expressed mRNAs and 308 differentially expressed lncRNAs from RNA sequencing analysis. GO analysis showed that the upregulated mRNAs in FLC were enriched in collagen fibril and extracellular matrix organization, while the downregulated mRNAs were enriched in xenobiotic metabolic and exogenous drug catabolic process. Furthermore, the upregulated mRNAs were enriched in PI3k-Akt signaling pathway based on KEGG pathway analysis, and in epithelial mesenchymal transition from GSEA analysis. we performed trans-target prediction analysis and identified 454 co-expressed pairs in FLC. Lastly, we screened and obtained potential therapeutic small molecule compounds using hub genes of FLC we identified. Conclusions: Our study revealed common mRNA and lncRNA expression profiles in FLC, and identified hub genes of DE mRNAs and lncRNA target genes, as well as small molecular compounds that could potentially be used as treatments. These results could contribute to further understanding of FLC and provides potential avenues for diagnosis and treatment.